D. Western Therapeutics Institute, Inc. (TYO:4576)
Japan · Delayed Price · Currency is JPY 88.00
0.00 (0.00%)
Aug 27, 2026, 3:30 PM JST
TYO:4576 Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,581 | 1,709 | 1,126 | 1,867 | 2,334 | 1,933 |
Cash & Short-Term Investments | 1,581 | 1,709 | 1,126 | 1,867 | 2,334 | 1,933 |
Cash Growth | 51.00% | 51.78% | -39.69% | -20.01% | 20.75% | -16.25% |
Receivables | 96 | 94 | 125 | 117 | 170 | 101 |
Inventory | 128 | 86 | 101 | 87 | 79 | 88 |
Other Current Assets | 92 | 131 | 123 | 66 | 76 | 40 |
Total Current Assets | 1,897 | 2,020 | 1,475 | 2,137 | 2,659 | 2,162 |
Property, Plant & Equipment | 12 | 9 | 11 | 10 | 10 | 4 |
Long-Term Investments | 137 | 137 | 138 | 138 | 162 | 129 |
Other Intangible Assets | 1 | 2 | 44 | 86 | 124 | 166 |
Other Long-Term Assets | 2 | 1 | 1 | 2 | 1 | 1 |
Total Assets | 2,049 | 2,169 | 1,669 | 2,373 | 2,956 | 2,462 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Current Portion of Long-Term Debt | 154 | 99 | 19 | 9 | 120 | 129 |
Current Income Taxes Payable | 22 | 66 | 99 | 173 | 75 | 51 |
Other Current Liabilities | 11 | 38 | 14 | 12 | 16 | 13 |
Total Current Liabilities | 187 | 203 | 132 | 194 | 211 | 193 |
Long-Term Debt | 429 | 506 | 778 | 875 | 847 | 210 |
Other Long-Term Liabilities | 25 | 26 | 26 | 25 | 27 | 25 |
Total Liabilities | 641 | 735 | 936 | 1,094 | 1,085 | 428 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 845 | 697 | 1,203 | 831 | 714 | 573 |
Additional Paid-In Capital | 1,429 | 1,280 | 3,261 | 2,889 | 2,772 | 2,631 |
Retained Earnings | -866 | -543 | -3,732 | -2,442 | -1,629 | -1,200 |
Comprehensive Income & Other | - | - | 1 | 1 | -1 | 2 |
Total Common Equity | 1,408 | 1,434 | 733 | 1,279 | 1,856 | 2,006 |
Minority Interest | - | - | - | - | 15 | 28 |
Shareholders' Equity | 1,408 | 1,434 | 733 | 1,279 | 1,871 | 2,034 |
Total Liabilities & Equity | 2,049 | 2,169 | 1,669 | 2,373 | 2,956 | 2,462 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 583 | 605 | 797 | 884 | 967 | 339 |
Net Cash (Debt) | 998 | 1,104 | 329 | 983 | 1,367 | 1,594 |
Net Cash Growth | 88.30% | 235.56% | -66.53% | -28.09% | -14.24% | -13.74% |
Net Cash Per Share | 18.69 | 23.03 | 9.37 | 30.93 | 46.12 | 54.34 |
Filing Date Shares Outstanding | 57.47 | 54.36 | 45.28 | 32.13 | 31.32 | 29.36 |
Total Common Shares Outstanding | 57.47 | 54.25 | 41.63 | 32.13 | 30.87 | 29.36 |
Working Capital | 1,710 | 1,817 | 1,343 | 1,943 | 2,448 | 1,969 |
Book Value Per Share | 24.50 | 26.43 | 17.61 | 39.81 | 60.12 | 68.33 |
Tangible Book Value | 1,407 | 1,432 | 689 | 1,193 | 1,732 | 1,840 |
Tangible Book Value Per Share | 24.48 | 26.40 | 16.55 | 37.13 | 56.10 | 62.67 |